Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease

Phase 1 Completed 80 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluate safety, tolerability, and pharmacokinetics of single doses of the investigational AAB-001 Vaccine in Japanese patients with Alzheimer's disease.

Timeline

Start: 2006-10
Primary completion: 2010-02
Completion: 2010-02

Publications

Arai H, Umemura K, Ichimiya Y, Iseki E, Eto K, Miyakawa K, Kirino E, Shibata N, Baba H, Tsuchiwata S. Safety and pharmacokinetics of bapineuzumab in a single ascending-dose study in Japanese patients with mild to moderate Alzheimer's disease. Geriatr Gerontol Int. 2016 May;16(5):644-50. doi: 10.1111/ggi.12516. Epub 2015 Jun 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	bapineuzumab	Monoclonal antibody	0.15 mg/kg	Intravenous
Subject	bapineuzumab	Monoclonal antibody	0.5 mg/kg	Intravenous
Subject	bapineuzumab	Monoclonal antibody	1 mg/kg	Intravenous

Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease

Summary

Timeline

Publications

Drugs

Indications